Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)’s stock price has increased by 2.37 compared to its previous closing price of 32.97. Despite this, the company has seen a gain of 1.90% in its stock price over the last five trading days.
, and the 36-month beta value for ARWR is at 1.02. Analysts have varying views on the stock, with 9 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases “World’s Most Powerful Data Center CPU”. It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We’ve put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
The average price suggested by analysts for ARWR is $63.62, which is $29.94 above the current market price. The public float for ARWR is 103.30M, and currently, shorts hold a 4.43% of that float. The average trading volume for ARWR on February 19, 2023 was 974.36K shares.
Arrowhead Pharmaceuticals Inc. (ARWR) Stock: Analyzing the Quarterly Movement
Arrowhead Pharmaceuticals Inc. (ARWR) has experienced a 1.90% rise in stock performance for the past week, with a -0.53% drop in the past month, and a 6.57% rise in the past quarter. The volatility ratio for the week is 4.38%, and the volatility levels for the past 30 days are at 4.71% for ARWR. The simple moving average for the last 20 days is -0.56% for ARWR stock, with a simple moving average of -5.63% for the last 200 days.
Analysts’ Opinion of ARWR
Many brokerage firms have already submitted their reports for ARWR stocks, with Morgan Stanley repeating the rating for ARWR by listing it as a “Equal-Weight.” The predicted price for ARWR in the upcoming period, according to Morgan Stanley is $41 based on the research report published on September 09th of the previous year 2022.
Robert W. Baird, on the other hand, stated in their research note that they expect to see ARWR reach a price target of $60, previously predicting the price at $71. The rating they have provided for ARWR stocks is “Outperform” according to the report published on May 11th, 2022.
Goldman gave a rating of “Buy” to ARWR, setting the target price at $85 in the report published on January 19th of the previous year.
ARWR Trading at -2.39% from the 50-Day Moving Average
After a stumble in the market that brought ARWR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.97% of loss for the given period.
Volatility was left at 4.71%, however, over the last 30 days, the volatility rate increased by 4.38%, as shares sank -0.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.44% upper at present.
During the last 5 trading sessions, ARWR rose by +1.90%, which changed the moving average for the period of 200-days by -20.87% in comparison to the 20-day moving average, which settled at $33.94. In addition, Arrowhead Pharmaceuticals Inc. saw -16.79% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ARWR starting from Waddill William D., who sale 3,200 shares at the price of $30.00 back on Jan 09. After this action, Waddill William D. now owns 28,950 shares of Arrowhead Pharmaceuticals Inc., valued at $96,000 using the latest closing price.
O’Brien Patrick, the COO and General Counsel of Arrowhead Pharmaceuticals Inc., sale 15,000 shares at $37.39 during a trade that took place back on Jan 05, which means that O’Brien Patrick is holding 413,375 shares at $560,850 based on the most recent closing price.
Stock Fundamentals for ARWR
Current profitability levels for the company are sitting at:
- -73.39 for the present operating margin
- +95.72 for the gross margin
The net margin for Arrowhead Pharmaceuticals Inc. stands at -72.39. Equity return is now at value -36.80, with -20.30 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 2.92.